Patents Assigned to GlaxoSmithKline Biological S.A.
  • Immunogenic composition
    Patent number: 9931397
    Abstract: The present application relates to an immunogenic composition comprising at least 2 conjugates of N. meningitidis capsular saccharide and protein carrier, wherein said conjugates comprise at least 2 different N. meningitidis capsular saccharides selected from the group consisting of MenA, MenC, MenY and MenW, wherein at least one capsular saccharide is conjugated to a protein carrier with a saccharide:protein ratio (w/w) between 1:2-1:5, and wherein at least one different capsular saccharide is conjugated to a protein carrier with a saccharide:protein ratio (w/w) between 5:1-1:1.99.
    Type: Grant
    Filed: June 23, 2006
    Date of Patent: April 3, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
  • IMMUNOGENIC COMPOSITION COMPRISING ELEMENTS OF C. DIFFICILE CDTB AND/OR CDTA PROTEINS
    Publication number: 20180043005
    Abstract: The present invention relates to immunogenic compositions comprising isolated Clostridium difficile CDTb and/or CDTa protein. In particular the isolated Clostridium difficile CDTb protein is suitably a truncated CDTb protein comprising the receptor binding domain or a mutated CDTb protein incapable of binding to CDTa, and the isolated Clostridium difficile CDTa protein is suitably a truncated CDTa protein which does not comprise the C-terminal domain. In particular the invention also relates to fusion proteins comprising a CDTa protein and a CDTb protein and also fusion proteins between an isolated Clostridium difficile toxin A protein and/or an isolated Clostridium difficile toxin B protein fused to a CDTb protein.
    Type: Application
    Filed: May 15, 2017
    Publication date: February 15, 2018
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventor: Cindy CASTADO
  • CMV ANTIGENS AND USES THEREOF
    Publication number: 20180015159
    Abstract: The invention relates to a recombinant human cytomegalovirus (CMV) protein dimeric complex comprising CMV gH protein or a complex-forming fragment thereof, and CMV UL116 or a complex-forming fragment thereof. Also provided herein are nucleic acids encoding said gH/UL116 dimeric complex, host cells for recombinant expression of said gH/UL116 dimeric complex, and the use of said gH/UL116 dimeric complex for use as a vaccine antigen.
    Type: Application
    Filed: January 22, 2016
    Publication date: January 18, 2018
    Applicant: GlaxoSmithKline Biologicals, S.A.
    Inventors: Luca BRUNO, Stefano CALO, Andrea CARFI, Mirko CORTESE, Marcello MEROLA
  • MAMMALIAN CELLS EXPRESSING CYTOMEGALOVIRUS ANTIGENS
    Publication number: 20170362278
    Abstract: This invention relates to cytomegalovirus (CMV) proteins suitable for vaccine uses. Provided herein are mammalian host cells, in particular CHO cells, in which the sequence(s) encoding CMV proteins gH, gL, pUL128, pUL130, pUL131 (or a complex-forming fragment thereof) are stably integrated into the genome.
    Type: Application
    Filed: October 29, 2015
    Publication date: December 21, 2017
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Andrea CARFI, Claudio CIFERRI, Irmgard HOFMANN, Holger LAUX, Anders LILJA, Yingxia WEN
  • Nucleotide Sequences, Vectors and Host Cells
    Publication number: 20170362309
    Abstract: The present invention relates to fusion proteins comprising fragments from toxin A and/or toxin B of Clostridium difficile, wherein the polypeptide elicits antibodies that neutralize toxin A or toxin B or both.
    Type: Application
    Filed: June 28, 2016
    Publication date: December 21, 2017
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventor: Cindy CASTADO
  • IMMUNOGENIC COMPOSITION
    Publication number: 20170340719
    Abstract: The present invention relates to immunogenic compositions comprising a Clostridium difficile (C. difficile) polypeptide and an aluminium-free adjuvant.
    Type: Application
    Filed: May 26, 2017
    Publication date: November 30, 2017
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Dominique BOUTRIAU, Sophie Marie Jeanne Valentine GERMAIN, Hugues WALLEMACQ
  • Hypo- and hyper-acetylated meningococcal capsular saccharides
    Patent number: 9827301
    Abstract: Capsular saccharides derived from serogroups W135 and Y of Neisseria meningitidis have altered levels of O-acetylation at the 7 and 9 positions of their sialic acid residues, and can be used to make immunogenic compositions. Relative to unmodified native saccharides, derivatives of the invention are preferentially selected during conjugation to carrier proteins, and conjugates of the derivatives show improved immunogenicity compared to native polysaccharides.
    Type: Grant
    Filed: May 1, 2014
    Date of Patent: November 28, 2017
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Paolo Costantino, Francesco Berti
  • COMPLEXES OF CYTOMEGALOVIRUS PROTEINS
    Publication number: 20170320916
    Abstract: An isolated human cytomegalovirus (HCMV) membrane protein complex that comprises gH, gL and at least one more HCMV glycoprotein is provided. In some embodiments the complex consists of gH, gL and gO. In other embodiments the complex consists of gH, gL, pUL128, pUL130 and pUL131A. Processes for expressing and purifying such complexes, and subsequent uses of such complexes in immunogenic compositions and vaccines, are also provided.
    Type: Application
    Filed: May 16, 2017
    Publication date: November 9, 2017
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Andrea CARFI, Yingxia Wen
  • Delivery of self-replicating RNA using biodegradable polymer particles
    Patent number: 9795668
    Abstract: Particle compositions comprising adsorbed RNA replicons as well as methods of making and using the same are described.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: October 24, 2017
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Siddhartha Jain, Manmohan Singh, Derek O'Hagan
  • Immunogenic composition
    Patent number: 9789179
    Abstract: The present application discloses an immunogenic composition comprising N. meningitidis capsular polysaccharides from at least one of serogroups A, C, W135 and Y conjugated to a carrier protein to produce a N. meningitidis capsular polysaccharide conjugate, wherein the average size of each N. meningitidis polysaccharide is above 50 kDa.
    Type: Grant
    Filed: June 23, 2006
    Date of Patent: October 17, 2017
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
  • VACCINE
    Publication number: 20170290905
    Abstract: The present invention relates to Human Rhinovirus (HRV) Virus-Like Particles (VLPs) and methods of making HRV VLPs.
    Type: Application
    Filed: September 17, 2015
    Publication date: October 12, 2017
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Cindy CASTADO, Steve LABBE, Patrick RHEAULT
  • Chemically defined medium for the industrial scale culture of a species of
    Patent number: 9765294
    Abstract: Chemically defined media for the industrial-scale culture of Bordetella species.
    Type: Grant
    Filed: September 11, 2014
    Date of Patent: September 19, 2017
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Philippe Marc Helene Dehottay, Philippe Goffin, Filipe Branco dos Santos, Bas Teusink
  • ULTRAFILTRATION FOR PREPARING OUTER MEMBRANE VESICLES
    Publication number: 20170252699
    Abstract: In place of a step of centrifugation during preparation of outer membrane vesicles (OMVs) from bacteria, the invention utilises ultrafiltration. This allows much larger amounts of OMV-containing supernatant to be processed in a much shorter time. Thus the invention provides a process for preparing bacterial OMVs, comprising a step of ultrafiltration. The ultrafiltration step is performed on an aqueous suspension of OMVs after they have been prepared from bacteria and the OMVs remain in suspension after the filtration step. The invention is particularly useful for preparing OMVs from Neisseria meningitidis.
    Type: Application
    Filed: May 19, 2017
    Publication date: September 7, 2017
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Roberto OLIVIERI, Fabio SABBATINI, Ilio MARSILI
  • NUCLEOTIDE SEQUENCES, VECTORS AND HOST CELLS
    Publication number: 20170247421
    Abstract: Polynucleotides encoding fusion proteins comprising fragments of toxin A and toxin B from Clostridium difficile are described, as well as vectors and host cells containing such polynucleotides.
    Type: Application
    Filed: March 21, 2017
    Publication date: August 31, 2017
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventor: Cindy CASTADO
  • antigenic composition
    Patent number: 9730992
    Abstract: Immunogenic compositions comprising an M72 related antigen, wherein the conductivity of the composition is 13 mS/cm or lower, or the concentration of salts of the composition is 130 mM or lower, and their use in medicine, are provided.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: August 15, 2017
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Stéphane André Georges Godart, Amina Laanan, Dominique Ingrid Lemoine
  • IMMUNOGENIC COMPOSITION
    Publication number: 20170209562
    Abstract: The present disclosure relates to the field of Neisserial immunogenic compositions and vaccines, their manufacture and the use of such compositions in medicine. In particular the present invention relates to compositions and methods involving the factor H binding protein (fHbp) antigen. The present inventors have recognised that fHbp is poorly expressed in neisserial strains of ST269 clonal complex (a subset of strains which seems to be growing in terms of numbers of reported cases of disease attributed to it), and vaccines comprising fHbp may be made more effective against said strains by formulating the vaccine with a further antigen that can elicit protection against these strains.
    Type: Application
    Filed: December 6, 2016
    Publication date: July 27, 2017
    Applicant: GlaxoSmithKline Biologicals S.A.
    Inventors: Jan POOLMAN, Nathalie Isabelle DEVOS, Cindy CASTADO, Vincent WEYNANTS
  • Fermentation of fastidious bacterial strain in perfusion suspension culture
    Patent number: 9701936
    Abstract: The present invention relates to improved processes for culturing bacteria, in particular to processes for perfusion suspension culturing of bacteria in a fermenter, wherein the culture medium including the bacteria is circulated over a separation system in alternating tangential flow, wherein the separation system removes a filtrate containing inhibitory metabolites from the culture medium.
    Type: Grant
    Filed: June 24, 2013
    Date of Patent: July 11, 2017
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Philippe Marc Helene Dehottay, Michael Lanero Fidalgo, Dominique Janssens, Marc Roger Fernand Orval
  • Vaccine comprising an oil in water emulsion
    Patent number: 9700605
    Abstract: The present invention provides an immunogenic composition comprising an antigen or antigen composition and an adjuvant composition comprising an oil in water emulsion, wherein said oil in water emulsion comprises 0.5-10 mg metabolizable oil, 0.5-11 mg tocol and 0.1-4 mg emulsifying agent, per human dose.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: July 11, 2017
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: William Ripley Ballou, Jr., Emmanuel Jules Hanon
  • Immunogenic composition
    Patent number: 9694064
    Abstract: The present invention relates to immunogenic compositions comprising a Clostridium difficile (C. difficile) polypeptide and an aluminum-free adjuvant.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: July 4, 2017
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Dominique Boutriau, Sophie Marie Jeanne Valentine Germain, Hugues Wallemacq
  • Complexes of cytomegalovirus proteins
    Patent number: 9683022
    Abstract: An isolated human cytomegalovirus (HCMV) membrane protein complex that comprises gH, gL and at least one more HCMV glycoprotein is provided. In some embodiments the complex consists of gH, gL and gO. In other embodiments the complex consists of gH, gL, pUL128, pUL130 and pUL131A. Processes for expressing and purifying such complexes, and subsequent uses of such complexes in immunogenic compositions and vaccines, are also provided.
    Type: Grant
    Filed: June 29, 2013
    Date of Patent: June 20, 2017
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Andrea Carfi, Yingxia Wen